Flagship refocuses stealth RNA biotech; Mesoblast enacts pay cuts for executives
Radial Therapeutics, a stealth-stage startup inside the biotech incubator Flagship Pioneering, is refocusing.
“Unfortunately, we found out recently that Radial has decided to stop pursuing the goal of drugging RNA with small molecules, effectively ending the company,” an employee posted to LinkedIn earlier this month. “While Flagship is trying to place everyone into other positions in their ecosystem, it isn’t a guarantee.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
